ClinicalTrials.gg
CompletedNCT02488733ESINODOPUpdated Oct 30, 2026

Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients

An interventional study of LSG and CMT in Type 2 Diabetes Mellitus, sponsored by Azienda Ospedaliera Santa Maria, Terni, Italy. Completed at 2 sites in Italy. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Azienda Ospedaliera Santa Maria, Terni, Italy · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy — 45 open to participants now, 61 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Italy.

Enrollment
297th of 321
30 · median 320
Started
2015
with 23 others
No phase
71 of 421
14 open now
Registered
216th of 421
by date

Among the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, this one is the 297th largest by enrollment of the 321 interventional ones that give a count, is one of 24 that started in 2015, is one of 71 with no phase, and was the 216th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

45 of the 421 studies in Diabetes Mellitus, Type 2 with a site in Italy are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 421 studies in Diabetes Mellitus, Type 2 with a site in Italy, or all of them as a file.
02

Study summary

Bariatric surgery is efficient in both inducing adequate weight loss and the control of glycemia in obese patients affected by Type 2 Diabetes Mellitus (T2DM).

Despite growing evidence suggesting that early performance of bariatric surgery on obese patients with T2DM offers the best opportunity to reach and maintain a remission of diabetes, no randomized clinical trials (RCT) have evaluated its efficiency in patients with new T2DM diagnosis.

The aim of this RCT is to compare bariatric surgery, and in particular Laparoscopic Sleeve Gastrectomy (LSG), with conventional medical therapy (CMT) in patients with new T2DM diagnosis that are obese (Body Mass Index, BMI of between 30 and 42 Kg/m2), to be recruited at two Italian diabetology centres (Terni and Rome).

The main objective of the present RCT is to investigate the efficacy of LSG as compared with CMT in inducing and maintaining both a resolution of T2DM (defined as HbA1c levels ≤6.0%, without active pharmacologic therapy or ongoing procedures) and the remission of T2DM through the evaluation of the criteria provided by the American Diabetes Association (ADA) at maximum follow-up of 6 years. The effects of the two treatments in terms of weight loss and the quality of life of the patient will also be taken into consideration.

Any positive results of this study will include preventing microvascular and macrovascular complications connected with diabetes, without the necessity to take medication, and at the same time the loss of excess body weight and improved quality of life (QOL).

Read the detailed description

Recent evidence suggests that, in obese patients with type 2 diabetes mellitus of long duration, and / or poorly controlled with conventional therapy, bariatric surgery promises diabetes remission rates significantly higher than those attainable with traditional treatment, irrespective of initial BMI and the loss of body weight of the patients.

This has ensured the growing conviction in the international scientific community that bariatric surgery should not be considered as an alternative to conventional obesity and diabetes therapies only after the failure of traditional treatments, but should be performed with the intent to prevent complications associated with these diseases, and therefore at their onset [23]. Furthermore, the use of BMI as the main parameter to guide the indication of bariatric surgery is increasingly being called into question with regard to the presence of comorbidities such as diabetes, as it is the distribution of obesity, together with the presence of comorbidities such as diabetes, rather than the degree of obesity that predicts the onset of related complications.

Bariatric surgery is currently regarded as a "last resort" for both the treatment of obesity and its associated comorbidities, such as diabetes, particularly in patients with a BMI ≤ 35. Despite this, it is now apparent that initial BMI and body weight loss resulting from bariatric surgery have no connection with the metabolic effects of the procedure, such as on the treatment of diabetes. In fact, according to the current national and international guidelines (which are based on a consensus dated 1991[6]), bariatric surgery may be considered in diabetic patients, with a BMI between 30 and 39.9 Kg/m2, only after the recorded failure of conventional medical therapies for obesity and diabetes.

This wait-and-see policy is due to the fact that bariatric surgery is a surgical procedure that is associated, depending on the procedure, with a certain rate of short and long term potential adverse events, and while in the short-medium term it has been shown to achieve significantly higher rates of remission from diabetes, when compared to medical therapy, there remain uncertainties about the durability of remission of diabetes and weight control after long follow-up periods. Essentially, therefore, the risk-benefit ratio has not allowed for the use of bariatric surgery as a first-line therapy for the treatment of type 2 diabetes in obese patients, and in particular in class 1 and 2 obesity. It can be hypothesized, however, that the performance of LSG at diagnosis of diabetes in obese patients can dramatically improve both the resolution/remission rate and the duration of resolution/remission from diabetes, and thus improve the protection against the development of vascular complications.

In fact, growing evidence suggests that the period of time between the diagnosis of diabetes and bariatric surgery is a determining factor in the achievement and duration of diabetes remission. It has also been observed that bariatric surgery is more effective than medical therapy in preventing diabetes in obese patients.

In the opinion of the authors, the early performance of LSG, also at the diagnosis of diabetes, could be crucial. This is hypothesized also on the basis of the well-known phenomenon of "glycemic legacy", according to which the greater the time elapsed between diabetes diagnosis and the achievement, with any form of therapy, of glycemic control targets, the lower the benefit in terms of protection from the development of vascular complications associated with diabetes [34]. It follows that blood glucose control in patients with newly diagnosed diabetes should be achieved through the implementation of appropriate treatments, including bariatric surgery, as quickly as possible after diagnosis. In this sense, bariatric surgery (and in particular, LSG) has been proven capable of promoting glycemic control in the short to medium term, in terms of the substantial and rapid reduction of glycated haemoglobin, (even 3 months after surgery), compared to conventional medical therapy in patients with longstanding diabetes (about 9 years on average). In the RCT conducted by Schauer et al., 3 months after sleeve gastrectomy, average HbA1c levels were reduced from an initial average value of 9.5% to 7%, while in the medical-therapy group they were reduced from an initial value of 8.9% to 7.7%,therefore significantly less effective than LSG. Thus irrespective of the rate of achievement and duration of eventual remission of diabetes (that in any case is already at present considerably higher than medical therapy in patients with longstanding and poorly controlled diabetes), patients undergoing sleeve gastrectomy (and bariatric surgery in general) could benefit from the procedure being performed on diagnosis of diabetes, and therefore as soon as possible, thanks to the ability to reach the HbA1c target level for glycemic control more easily and quickly than with medical therapy. This would have a proven protective effect on long-term vascular complications, irrespective of the duration of the glycemic control and the achievement of any remission on the basis of the concept of "glycemic legacy" and "metabolic memory" , through the analysis of the results of the largest and most prestigious international randomized clinical trials on the treatment of diabetes (UKPDS, DCCT/EDIC, ACCORD and VATD trials).

The phenomenon of metabolic memory refers to the fact that the UKPDS and DCCT / EDIC studies have demonstrated that even a transitory period of aggressive glycemic control, such as that attainable after bariatric surgery, is capable of inducing a beneficial "metabolic memory", with the effect of reducing microvascular complications over time, regardless of subsequent maintenance of glycemic control [32].

Then the rationale for the use of bariatric surgery at diagnosis of type 2 diabetes mellitus is based not only on the hypothesis of the attainment of early and sustained glycemic control in obese patients, but also on a variety of scientific evidence that suggests that the precocity of its performance is a positive predictor of remission and of the long-term maintenance of diabetes remission.

As previously mentioned, the superiority of bariatric surgery to conventional medical therapy in obese patients (even with BMI less than 30) with diabetes of long duration, and / or poorly controlled with conventional therapy, in terms of attaining glycemic control, has clearly been demonstrated , even if for medium-short follow-up periods [1]. When applied in obese patients with new onset diabetes it might therefore subvert the risk-benefit ratio that now prevents its use as a first-line therapy, thanks to an increase in the rate of remission of diabetes and its endurance, as well as a reduction of the long-term vascular complications of diabetes.

In conclusion, a recent American Society of Metabolic and Bariatric Surgery (ASMBS) position statement noted that that class 1 obesity requires effective treatment, as it represents a significant health problem, and that treatment should involve the use of bariatric surgery. Indeed, recent randomized studies have demonstrated both the effectiveness, in terms of weight loss and control of comorbidity, and the safety of some bariatric surgical procedures, including sleeve gastrectomy, in this specific group of patients (Class 1 Obesity).

These observations suggest that T2DM could be treated with bariatric surgery as early as possible, also at the time of diagnosis.

It can be hypothesized that performing LSG at T2DM diagnosis can offer the maximum benefits in terms of both the attainment and duration of T2DM resolution/remission, with the potential to thus prevent micro and macrovascular complications without the need to take medication. Other positive aspects include the possibility to achieve appropriate weight loss and a related improvement in the quality of life. In this randomized trial LSG will be compared with conventional medical therapy in the treatment of T2DM at onset in obese patients with a BMI of between 30 and 42 Kg/m2.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • type 2 diabetes mellitus
  • obesity
  • laparoscopic sleeve gastrectomy
  • bariatric surgery
  • metabolic surgery
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. No for laparoscopic surgery or general anaesthesia.
  2. Age ≥20 and ≤65 years.
  3. of between 30 and 42 kg/m2.
  4. Documented new diagnosis of Type 2 Diabetes Mellitus obtained according to the following American Diabetes Association parameters: fasting blood glucose ≥ 126 mg/dl (7.0 mmol/l) and/or ≥ 6.5% and no more than 8 months from enrollment in the study.

Exclusion criteria

Exclusion Criteria:

  1. Previous bariatric surgery or major abdominal surgery.
  2. Patients with T2DM diagnosis treated with insulin.
  3. Evidence of complications connected to diabetes at any stage (diabetic retinopathy, diabetic nephropathy/microalbuminuria, cardiovascular disease or neuropathy).
  4. Cardiovascular diseases such as ischemia / coronary artery disease, arrhythmia, peripheral vascular diseases, congestive heart failure, history of heart attacks.
  5. Kidney diseases including nephro-vascular hypertension, stenosis of the renal artery or chronic renal insufficiency.
  6. Pregnancy
  7. Diagnosis of psychiatric illness (including dementia, severe depression, history of suicide attempts) or abuse of alcohol or drugs in the previous 5 years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Laparoscopic Sleeve Gastrectomy (LSG)

    In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.

    Procedure: LSG · Drug: CMT

  • Other
    Conventional medical therapy (CMT)

    CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.

    Drug: CMT

Interventions

  • ProcedureLSG

    In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines

  • DrugCMT

    CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)\[50\] and determined on an individual basis \[52\].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .

06

What researchers measure

Primary outcomes

  1. Rate of patients achieving diabetes resolution

    HbA1c levels ≤6.0%, without active pharmacologic therapy or ongoing procedures

    Time frame: Assessed up to 1 year after randomization

Secondary outcomes

  1. Rate of patients achieving diabetes resolution

    diabetes resolution

    Time frame: assessed at 2, 3, 4, 5 and 6 years after randomization

  2. Rate of patients achieving diabetes complete remission (American Diabetes Association criteria)

    diabetes complete remission

    Time frame: assessed at 2, 3, 4, 5, and 6 years after randomization

  3. Rate of patients achieving HbA1c levels ≤6.5%,

    achieving HbA1c levels ≤6.5%,

    Time frame: assessed at 1, 2, 3, 4, 5,and 6 years after randomization

  4. Rate of patients achieving HbA1c levels ≤6.5%,

    achieving HbA1c levels ≤6.5%,

    Time frame: assessed up at 1, 2, 3, 4, 5,and 6 years after randomization

  5. Rate of patients achieving prolonged remission (American Diabetes Association criteria)

    achieving prolonged remission

    Time frame: Assessed up at 6 years after randomization

  6. Time to achievement (in days) of complete remission

    complete remission

    Time frame: Assessed up at 2 years after randomization

  7. Time to achievement (in days) of prolonged remission

    prolonged remission

    Time frame: Assessed up at 6 years after randomization

  8. Total duration of the period with diabetes resolution

    diabetes resolution

    Time frame: Assessed at 3 and 6 years

  9. Total duration of the period in complete remission

    complete remission

    Time frame: Assessed at 3 and 6 years

  10. Total duration of the time period with HbA1c ≤ 6.0% irrespective of any active pharmacologic therapy or ongoing procedures

    Total duration of the time period with HbA1c ≤ 6.0% irrespective of any active

    Time frame: Assessed at 3 and 6 years

  11. Total duration of the period with HbA1c levels ≤6.5%, without active pharmacologic therapy or ongoing procedures

    Total duration of the period with HbA1c levels ≤6.5%, without active pharmacologic

    Time frame: Assessed at 3 and 6 years

  12. Total duration of the period with HbA1c levels ≤6.5% irrespective of any active pharmacologic therapy or ongoing procedures

    Total duration of the period with HbA1c levels ≤6.5% irrespective of any active

    Time frame: Assessed at 3 and 6 years

  13. Average value and changes from baseline, during the follow-up period, until the predefined time end-points of anthropometric, blood, urinary and QoL parameters.

    Average value and changes from baseline, during the follow-up period, until the

    Time frame: Assessed up at 6 years after randomization

  14. Rate of patients with effective weight loss (defined as % Excess Weight Loss > 50%)

    Rate of patients with effective weight loss (defined as % Excess Weight Loss \> 50%)

    Time frame: Assessed at 2 ,4, 6 years after randomization

  15. Rate of patients with hypertension and / or requiring antihypertensive therapy

    Rate of patients with hypertension and / or requiring antihypertensive therapy

    Time frame: Assessed at 2,4, 6 years after randomization

  16. Rate of patients with dyslipidemia and / or that require drug therapy for dyslipidemia

    Rate of patients with dyslipidemia and / or that require drug therapy for dyslipidemia

    Time frame: Assessed at 2,4 6 years after randomization

  17. Complications related to diabetes, or its pharmacological treatment, as well as those resulting from bariatric surgery.

    Complications related to diabetes, or its pharmacological treatment, as well as those

    Time frame: Assessed at 2,4 6 years after randomization

  18. Renal (onset of nephropathy or microalbuminuria), cardiovascular (defined as the occurrence of myocardial infarction, congestive heart failure or stroke), and ocular damage (development of diabetic retinopathy), and diabetes-related peripheral neuropathy

    Renal (onset of nephropathy or microalbuminuria), cardiovascular (defined as the occurrence of myocardial infarction, congestive heart failure or stroke), and ocular damage (development of diabetic retinopathy), and diabetes-related peripheral neuropathy

    Time frame: Assessed at 2,4, 6 years after randomization

07

Study locations

2 sites
  • Ospedale Sandro Pertini
    Rome, Italy
  • Azienda Ospedaliera Santa Maria
    Terni, 05100, Italy
08

References and documents

Publications

  • Trastulli S, Parisi A, Grandone I, Fontana L, Desiderio J, Giannarelli D, Cirocchi R, Luca G, Palazzi M, Fatati G, D'Angelo P, Tebala GD. Laparoscopic sleeve gastrectomy versus conventional medical therapy in patients with newly diagnosed type 2 diabetes and body mass index 30-42 Kg/m2: 1-year results of a randomized clinical trial. J Endocrinol Invest. 2026 Aug 13. doi: 10.1007/s40618-026-03021-z. Online ahead of print. PubMed 42593716 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Dec 2015, a primary completion of Jun 2023 and a completion of Jun 2023. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Mar 2028 → Jun 2023 and completion Mar 2028 → Jun 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2015
First posted
Jul 2, 2015
Start
Dec 2015
Primary completionActual
Jun 2023was Mar 2028
CompletionActual
Jun 2023was Mar 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Primary completion
Mar 2028→Jun 2023 (actual)
Oct 30, 2026
Study completion
Mar 2028→Jun 2023 (actual)
Oct 30, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42593716 ↗
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42593716 ↗
    Primary completion Mar 2028→Jun 2023 (now actual)
    Study completion Mar 2028→Jun 2023 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02488733
Lead sponsor
Azienda Ospedaliera Santa Maria, Terni, Italy
Responsible party
Stefano Trastulli (Azienda Ospedaliera Santa Maria, Terni, Italy, Azienda Ospedaliera Santa Maria, Terni, Italy) — Principal investigator
First posted
Jul 2, 2015
Start date
Dec 2015
Primary completion
Jun 2023
Completion
Jun 2023
Last update
Oct 30, 2026

Study contacts

Stefano Trastulli, MD
principal investigator · Azienda Ospedaliera Santa Maria di Terni

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion